LEADER 04943nam  2200613Ia 450 
001 9910457486903321
005 20200520144314.0
010   $a88-97419-08-9
035   $a(CKB)2550000000083051
035   $a(EBL)837840
035   $a(OCoLC)773565234
035   $a(SSID)ssj0000633222
035   $a(PQKBManifestationID)11445828
035   $a(PQKBTitleCode)TC0000633222
035   $a(PQKBWorkID)10617043
035   $a(PQKB)11154902
035   $a(MiAaPQ)EBC837840
035   $a(Au-PeEL)EBL837840
035   $a(CaPaEBR)ebr10572354
035   $a(EXLCZ)992550000000083051
100   $a20120705d2011      uy             0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 10$aChemotherapy regimens in rare solid tumors$b[electronic resource] /$fAlessandro Gommandone
210   $aTorino $cSEEd$d2011
215   $a1 online resource (144 p.)
300   $aDescription based upon print version of record.
311   $a88-97419-07-0 
320   $aIncludes bibliographical references.
327   $aTitle page; Colophon; Table of contets; Preface; 1Rare tumors of the thorax; Mesothelioma; Mesothelioma: Cisplatin + Pemetrexed; Mesothelioma: Carboplatin + Pemetrexed; Mesothelioma: Cisplatin + Gemcitabine; Mesothelioma: Cisplatin + Doxorubicin; Mesothelioma: Pemetrexed; Mesothelioma: Pemetrexed + Gemcitabine; Mesothelioma: Gemcitabine + Cisplatin; Thymoma; Thymoma: PAC; Thymoma: PACE; Thymoma: ADOC; Thymoma: PE (EORTC); 2Endocrine glands tumors; Anaplastic thyroid carcinoma; Anaplastic thyroid carcinoma: Doxorubicin + Cisplatin; Anaplastic thyroid carcinoma: Doxorubicin
327   $aAnaplastic thyroid carcinoma: Paclitaxel + GemcitabineMedullary thyroid carcinoma; Medullary thyroid carcinoma: CVD; Medullary thyroid carcinoma: Sz/M; Carcinoma of parathyroid; Parathyroid carcinoma: CFuD; Parathyroid carcinoma: Dacarbazine; Adrenocortical carcinoma; Adrenocortical carcinoma: Mitotane; Adrenocortical carcinoma: EDP/M; Adrenocortical carcinoma: EP + Mitotane; Adrenocortical carcinoma: Sz/M; Feocromocitoma; Feocromocitoma: CVD; 3Neuroendocrine tumors; Gastroenteropancreatic neuroendocrine tumors (GEP); GEP: Streptozotocin + Doxorubicin; GEP: Streptozotocin + 5-Fluorouracil
327   $aGEP: FDEGEP: IFN; GEP: Octreotide LAR; GEP: Lanreotide; GEP: DTIC; Poorly-differentiated neuroendocrine tumor of different sites; Poorly-differentiated neuroendocrine tumor: PE; Poorly-differentiated neuroendocrine tumor: CAV; Poorly-differentiated neuroendocrine tumor: Topotecan; Poorly-differentiated neuroendocrine tumor: 5-Fluorouracil + Streptozotocin; Poorly-differentiated neuroendocrine tumor: EC; Poorly-differentiated neuroendocrine tumor: Etoposide orally; Poorly-differentiated neuroendocrine tumor: PEC; 4Rare gynecological tumors; Vulvar cancers
327   $aVulvar cancer: Radiotherapy + Cisplatin + 5-FluorouracilVulvar cancer: FUMIR (5-Fluorouracil + Mitomycin C + Radiotherapy); Vulvar cancer: Cisplatin + Bleomycin; Vulvar cancer: Cisplatin + 5-Fluorouracil; Vulvar cancer: Cisplatin + Vinorelbine; Uterine sarcomas; Uterine sarcomas (Leiomyosarcoma): HD-IFO; Uterine sarcomas (Leiomyosarcoma): Dacarbazine; Uterine sarcomas (Leiomyosarcoma): Dacarbazine; Uterine sarcomas (Leiomyosarcoma): Doxorubicin; Uterine sarcomas (Leiomyosarcoma): Doxorubicin + Ifosfamide; Uterine sarcomas (Leiomyosarcoma): MAID; Uterine sarcomas (Leiomyosarcoma): Trabectedin
327   $aUterine sarcomas (Leiomyosarcoma): Gemcitabine + DocetaxelCarcinosarcoma (mixed mu?llerian tumor): ITP; Carcinosarcoma (mixed mu?llerian tumor): TAP; Vaginal carcinoma; Vaginal carcinoma: Cisplatin + Vinorelbine; Vaginal carcinoma: Cisplatin + Bleomycin; Vaginal carcinoma: BIP; Vaginal carcinoma: BOMP; Vaginal carcinoma: Cisplatin + 5-Fluorouracil; Vaginal carcinoma: Cisplatin + Paclitaxel; Vaginal carcinoma: Carboplatin + Paclitaxel; 5Rare tumors of male genital tract; Testicular tumors and disgerminomas; Testicular tumors and disgerminomas: BEP; Testicular tumors: PVB
327   $aTesticular tumors: VeIP (rescue regimen)
330   $aRare tumors are an increasing problem in oncology. Aim of this book is to offer a help in spreading the knowledge of low-incidence tumors in oncology. Each chapter provides brief information about the epidemiology of and clinical aspects for every RT; and, following each chemotherapy schedule, we report a short description of the hematologic toxicities related to the treatment.
606   $aTumors
606   $aChemotherapy
608   $aElectronic books.
615  0$aTumors.
615  0$aChemotherapy.
676   $a617.4/4
676   $a617.44
700   $aComandone$b Alessandro$0903683
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910457486903321
996   $aChemotherapy regimens in rare solid tumors$92020004
997   $aUNINA